First blog in a series by Lisa Crump, founder of Cairn Ventures and Managing Partner, Sofia Fund. View Part II here. View Part III here.
As co-founder of Stratasys, Inc., a pioneering 3D printing technology company, I worked with a team of remarkable, risk-taking contributors – talented employees and managers, skilled board members and advisors, early investors, far-sighted customers, supportive vendors and a visionary co-founder.…
Pittsburgh, PA, March 26, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders caused by membrane trafficking dysfunction, today announced the appointment of Lisa Ricciardi to its Board of Directors.…
Joylux to be honored at the Angel Capital Association’s 2019 Summit as a top-three finalist for the prestigious Luis Villalobos Award
Seattle, WA, March 25, 2019 — Joylux, a leading FemTech company using high-tech solutions to improve vaginal health for postpartum and menopausal women, has been named one of the top three most ingenious and innovative companies funded by Angel Capital Association (ACA) members, a membership of 14,000+ accredited angel investors.…
Rebiotix is highlighted in The Future of Healthcare series under the headline The Future of Healthcare: “In the future we might be able to take microbes from a healthy person and using them to cure sick people” With Lee Jones, CEO of Rebiotix Inc.…
Oculogica is highlighted in the Community section under the headline The Future of Healthcare “Tracking a person’s eye movements to diagnose brain injuries” with Dr. Uzma Samadani of Oculogica. Read the entire article here:
Minneapolis, MN, February 28, 2019 — Sofia Fund, a leading angel investment group focused on high-growth, women-led companies, today announced its most recent investment in Landit, a technology platform that increases the success and engagement of women and diverse groups in the workplace.…
Pittsburgh, PA, February 21, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders, today announced the issuance by the European Patent Office of a composition of matter patent covering Elayta™, Cognition’s lead clinical stage compound in development for individuals with Alzheimer’s disease. …
Oculogica is the first highlight of the JAMA news section in this week’s issue: https://jamanetwork.com/journals/jama/fullarticle/2725217
Elayta Crossed Blood Brain Barrier and Reached CNS Levels Associated in Preclinical Studies with Cognitive Improvement
Pittsburgh, PA, February 19, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative disorders, announced today the publication of clinical data from the Company’s Phase 1 trial of Elayta™ (CT1812) in Alzheimer’s & Dementia: Translational Research & Clinical Interventions.…
Oculogica receives FDA Marketing Authorization for EyeBOX®, the first non-invasive, baseline-free test for concussion. Oculogica is a pioneer in algorithm-based neurodiagnostics.